# Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

> **NCT03350178** · PHASE2 · TERMINATED · sponsor: **MaaT Pharma** · enrollment: 8 (actual)

## Conditions studied

- Intensive Care Units
- Fecal Microbiota Transplantation

## Interventions

- **DRUG:** fecal microbiota transfer

## Key facts

- **NCT ID:** NCT03350178
- **Lead sponsor:** MaaT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-15
- **Primary completion:** 2019-02-19
- **Final completion:** 2019-02-19
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** recruitment shortened
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350178, "Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03350178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*